Increased Autoreactive CD8<sup>+</sup> T Cells to Apolipoprotein B Epitopes in Patients With Severe Coronary Artery Disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42488951.
- Also identified by DOI 10.1161/CIRCRESAHA.125.326804.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Atherosclerosis is a chronic inflammatory disease with a strong autoimmune component, marked by the detection of autoreactive T cells and autoantibodies. Recent single-cell RNA sequencing studies have shown that atherosclerotic plaques contain clonally expanded CD8<sup>+</sup> T cells. One of the known atherosclerosis autoantigens is APOB (apolipoprotein B). However, autoreactive CD8<sup>+</sup> T cells to APOB in humans have not been described. We studied CD8<sup>+</sup> T-cell reactivity to human leukocyte antigen-A*02:01-restricted APOB epitopes, starting with in silico epitope prediction. We used peripheral blood mononuclear cells from human leukocyte antigen-A02:01+ healthy subjects to test the top 64-ranked peptides for their potential to elicit a CD8<sup>+</sup> T-cell response. Antigen-specific responses were assessed using activation-induced marker assays, intracellular cytokine staining, and IFNγ (interferon gamma) ELISpot assays. Some APOB peptides triggered robust CD8<sup>+</sup> T-cell activation with effector memory features, and expression of cytokines and cytotoxic molecules. Five immunodominant epitopes spanning 2 APOB regions accounted for most of the response and elicited significant T-cell activation in healthy donors that was increased in clinical samples from patients with severe coronary artery disease. The discovery of immunodominant major histocompatibility complex class I-restricted APOB epitopes suggests a new perspective for immune-based interventions to mitigate atherosclerosis.